Hi there, Thank you for subscribing to MarketBeat Daily Ratings. We're excited to have you onboard! Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. Please take a moment to confirm your subscription by clicking the link below. You may not receive your daily ratings newsletter without confirming your subscription. Click Here to Confirm Your Subscription to MarketBeat Daily Ratings Thank you again for subscribing. We look forward to being an important part of your investing journey.
Matthew Paulson
Founder and CEO, MarketBeat.
Confirm Your Subscription to MarketBeat Daily Ratings Here
For Your Education and Enjoyment 3 Under-the-Radar Biotechs Under $5 That Could Soar 200%Written by Chris Markoch. Published 9/9/2025. 
Key Points - Hoth Therapeutics is advancing mRNA-based therapies for cancer and obesity, with analyst targets implying over 150% upside.
- Silo Pharma combines pre-clinical psychedelic therapies with an obesity drug collaboration and a unique crypto treasury strategy.
- Anixa Biosciences develops cancer immunotherapies in partnership with leading institutions, with nearly 200% analyst upside potential.
Biotechnology stocks are generally considered speculative. Many companies remain in pre-clinical or clinical stages, with no profits and often no revenue, so any significant payoff could be years away. Yet these penny stocks—trading under $5—attract traders seeking quick technical gains. For investors with patience, small-cap biotech stocks can offer the opportunity to build positions with significant long-term upside. Below are three under-the-radar biotechs trading below $5 that could reward steadfast investors. Hoth: Pre-Clinical Cancer & Obesity Candidate Hoth Therapeutics Inc. (NASDAQ: HOTH) leads this list, with shares up 98% in 2025. Still, at about $1.50, the stock sits roughly 35% below its January peak. Hoth's pipeline spans oncology and weight-loss treatments. Its lead oncology asset, HT-KIT, uses mRNA technology to target gastrointestinal stromal tumors, systemic mastocytosis, and certain leukemias. In vitro tests showed over 80% knockdown of KIT expression, the key oncogenic driver in these aggressive cancers. Only two of Hoth's six candidates are in clinical trials, so the company remains pre-revenue. The obesity program, HT-VA, is based on VA-licensed technology and taps the booming weight-loss market. Analysts set a consensus price target of $4, implying about 150% upside. Silo Pharma: Psychedelics, Obesity Partnership & Crypto Strategy Silo Pharma Inc. (NASDAQ: SILO) is down 29% in 2025 but up over 7% in the past three months after signing a non-binding letter of intent for a 50/50 joint venture with Hoth to co-develop HT-VA. If finalized, this deal could give Silo exposure to a global obesity treatment market projected to exceed $100 billion. Separately, Silo focuses on "novel formulations of traditional and psychedelic therapeutics." Its pipeline includes four pre-clinical candidates, such as SP-26 for fibromyalgia and SPU-16 for multiple sclerosis. Adding a unique twist, Silo recently unveiled a cryptocurrency treasury strategy, targeting Bitcoin, Ethereum, and Solana. The plan uses staking to generate yield while emphasizing capital preservation. Anixa: Micro-Cap Oncology Play with Strategic Partnerships Anixa Biosciences (NASDAQ: ANIX) is slightly further along, with two of its five candidates in Phase 1 trials. One program is a CAR-T immunotherapy for ovarian cancer that engineers T cells to attack tumor cells. The other uses vaccine technology to elicit tumor-specific antigens. Anixa advances its pipeline through partnerships with the Moffitt Cancer Center, the Cleveland Clinic, and the U.S. Department of Defense. Though coverage is light, three analysts have set a consensus target of $10, suggesting nearly 200% upside. These sub-$5 biotechs illustrate the high-risk, high-reward nature of early-stage biotech. Investors with conviction and patience may find significant long-term gains if clinical programs succeed.
| 
